Skip to main content
Have a personal or library account? Click to login
Medical Management of Aortic Disease: If They Don’t Need Surgery, What Do They Need? Cover

Medical Management of Aortic Disease: If They Don’t Need Surgery, What Do They Need?

By:  and    
Open Access
|Mar 2023

References

  1. Isselbacher EM, Preventza O, Black JH, et al. 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2022 Dec 13;146(24):e334e482. doi: 10.1161/CIR.0000000000001106
  2. Danyi P, Elefteriades JA, Jovin IS. Medical therapy of thoracic aortic aneurysms: are we there yet? Circulation. 2011 Sep 27;124(13):146976. doi: 10.1161/CIRCULATIONAHA.110.006486
  3. Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC 3rd. Angiotensin II blockade and aortic-root dilation in Marfan’s syndrome. N Engl J Med. 2008 Jun 26;358(26):278795. doi: 10.1056/NEJMoa0706585
  4. Koullias GJ, Ravichandran P, Korkolis DP, Rimm DL, Elefteriades JA. Increased tissue microarray matrix metalloproteinase expression favors proteolysis in thoracic aortic aneurysms and dissections. Ann Thorac Surg. 2004 Dec;78(6):210610; discussion 2110-1. doi: 10.1016/j.athoracsur.2004.05.088
  5. Stein LH, Berger J, Tranquilli M, Elefteraides JA. Effect of statin drugs on thoracic aortic aneurysms. Am J Cardiol. 2013 Oct 15;112(8):12405. doi: 10.1016/j.amjcard.2013.05.081
  6. Jovin IS, Duggal M, Ebisu K, et al. Comparison of the effect on long-term outcomes in patients with thoracic aortic aneurysms of taking versus not taking a statin drug. Am J Cardiol. 2012 Apr 1;109(7):10504. doi: 10.1016/j.amjcard.2011.11.038
  7. Allar BG, Swerdlow NJ, de Guerre LEVM, et al. Preoperative statin therapy is associated with higher 5-year survival after thoracic endovascular aortic repair. J Vasc Surg. 2021 Dec;74(6):19962005. doi: 10.1016/j.jvs.2021.05.057
  8. Kent KC, Zwolak RM, Egorova NN, et al. Analysis of risk factors for abdominal aortic aneurysm in a cohort of more than 3 million individuals. J Vasc Surg. 2010 Sep;52(3):53948. doi: 10.1016/j.jvs.2010.05.090
  9. Gadowski GR, Pilcher DB, Ricci MA. Abdominal aortic aneurysm expansion rate: effect of size and beta-adrenergic blockade. J Vasc Surg. 1994 Apr;19(4):72731. doi: 10.1016/s0741-5214(94)70048-6
  10. Xiong X, Wu Z, Qin X, et al. Meta-analysis suggests statins reduce mortality after abdominal aortic aneurysm repair. J Vasc Surg. 2022 Jan;75(1):356362.e4. doi: 10.1016/j.jvs.2021.06.033
  11. Wemmelund H, Høgh A, Hundborg HH, Thomsen RW, Johnsen SP, Lindholt JS. Statin use and rupture of abdominal aortic aneurysm. Br J Surg. 2014 Jul;101(8):96675. doi: 10.1002/bjs.9517
  12. Smith, SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006 May 16;113(19):236372. doi: 10.1161/CIRCULATIONAHA.106.174516
  13. Chung AWY, Yang HH, Radomski MW, van Breemen C. Long-term doxycycline is more effective than atenolol to prevent thoracic aortic aneurysm in marfan syndrome through the inhibition of matrix metalloproteinase-2 and -9. Circ Res. 2008 Apr 25;102(8):e7385. doi: 10.1161/CIRCRESAHA.108.174367
  14. Pasternak B, Inghammar M, Svanström H. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. BMJ. 2018 Mar 8;360:k678. doi: 10.1136/bmj.k678
  15. Gopalakrishnan C, Bykov K, Fischer MA, Connolly JG, Gagne JJ, Fralick M. Association of Fluoroquinolones With the Risk of Aortic Aneurysm or Aortic Dissection. JAMA Intern Med. 2020 Dec 1;180(12):15961605. doi: 10.1001/jamainternmed.2020.4199
  16. Elefteriades JA, Farkas EA. Thoracic aortic aneurysm clinically pertinent controversies and uncertainties. J Am Coll Cardiol. 2010 Mar 2;55(9):84157. doi: 10.1016/j.jacc.2009.08.084
  17. Hatzaras IS, Bible JE, Koullias GJ, Tranquilli M, Singh M, Elefteriades JA. Role of exertion or emotion as inciting events for acute aortic dissection. Am J Cardiol. 2007 Nov 1;100(9):14702. doi: 10.1016/j.amjcard.2007.06.039
  18. Judge DP, Dietz HC. Marfan’s syndrome. Lancet. 2005 Dec 3;366(9501):196576. doi:10.1016/S0140-6736(05)67789-6
  19. Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006 Apr 7;312(5770):11721. doi: 10.1126/science.1124287
  20. Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan’s syndrome. N Engl J Med. 1994 May 12;330(19):133541. doi: 10.1056/NEJM199405123301902
  21. Mullen M, Jin XY, Child A, et al. Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial. Lancet. 2019 Dec 21;394(10216):22632270. doi: 10.1016/S0140-6736(19)32518-8
  22. Groenink M, den Hartog AW, Franken R, et al. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. Eur Heart J. 2013 Dec;34(45):3491500. doi: 10.1093/eurheartj/eht334
  23. Lacro RV, Dietz HC, Sleeper LA, et al. Atenolol versus losartan in children and young adults with Marfan’s syndrome. N Engl J Med. 2014 Nov 27;371(22):206171. doi: 10.1056/NEJMoa1404731
  24. Al-Abcha A, Saleh Y, Mujer M, et al. Meta-analysis Examining the Usefulness of Angiotensin Receptor blockers for the Prevention of Aortic Root Dilation in Patients With the Marfan Syndrome. Am J Cardiol. 2020 Aug 1;128:101106. doi: 10.1016/j.amjcard.2020.04.034
  25. Gallo EM, Loch DC, Habashi JP, et al. Angiotensin II-dependent TGF-β signaling contributes to Loeys-Dietz syndrome vascular pathogenesis. J Clin Invest. 2014 Jan;124(1):44860. doi: 10.1172/JCI69666
  26. Brooke BS, Arnaoutakis G, McDonnell NB, Black JH 3rd. Contemporary management of vascular complications associated with Ehlers-Danlos syndrome. J Vasc Surg. 2010 Jan;51(1):1318; discussion 138-9. doi: 10.1016/j.jvs.2009.08.019
  27. Lum YW, Brooke BS, Black JH 3rd. Contemporary management of vascular Ehlers-Danlos syndrome. Curr Opin Cardiol. 2011 Nov;26(6):494501. doi: 10.1097/HCO.0b013e32834ad55a
  28. Frank M, Adham S, Seigle S, et al. Vascular Ehlers-Danlos Syndrome: Long-Term Observational Study. J Am Coll Cardiol. 2019 Apr 23;73(15):19481957. doi:10.1016/j.jacc.2019.01.058
  29. Baderkhan H, Wanhainen A, Stenborg A, Stattin EL, Björck M. Celiprolol Treatment in Patients with Vascular Ehlers-Danlos Syndrome. Eur J Vasc Endovasc Surg. 2021 Feb;61(2):326331. doi: 10.1016/j.ejvs.2020.10.020
  30. Ong KT, Perdu J, de Backer J, et al. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. Lancet. 2010 Oct 30;376(9751):147684. doi: 10.1016/S0140-6736(10)60960-9
  31. Erbel R, Abyohans V, Boileau C, et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2014 Nov 1;35(41):2873926. doi: 10.1093/eurheartj/ehu281
  32. Daily PO, Trueblood HW, Stinson EB, Wuerflein RD, Shumway NE. Management of acute aortic dissections. Ann Thorac Surg. 1970 Sep;10(3):23747. doi: 10.1016/s0003-4975(10)65594-4
  33. Tsai TT, Nienaber CA, Eagle KA. Acute aortic syndromes. Circulation. 2005 Dec 13;112(24):380213. doi: 10.1161/CIRCULATIONAHA.105.534198
  34. Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. J Am Coll Cardiol. 2010 Apr 6;55(14):e27e129. doi: 10.1016/j.jacc.2010.02.015
  35. Hong JC, Le Huu A, Preventza O. Medical or endovascular management of acute type B aortic dissection. J Thorac Cardiovasc Surg. 2022 Oct;164(4):10581065. doi: 10.1016/j.jtcvs.2021.03.127
  36. Suzuki T, Isselbacher EM, Nienaber CA, et al. Type-selective benefits of medications in treatment of acute aortic dissection (from the International Registry of Acute Aortic Dissection [IRAD]). Am J Cardiol. 2012 Jan 1;109(1):1227. doi: 10.1016/j.amjcard.2011.08.012
  37. Chen SW, Chan YH, Lin CP, et al. Association of Long-term Use of Antihypertensive Medications With Late Outcomes Among Patients With Aortic Dissection. JAMA Netw Open. 2021 Mar 1;4(3):e210469. doi: 10.1001/jamanetworkopen.2021.0469
  38. Svensson LG, Arafat A, Roselli EE, et al. Inflammatory disease of the aorta: patterns and classification of giant cell aortitis, Takayasu arteritis, and nonsyndromic aortitis. J Thorac Cardiovasc Surg. 2015 Feb;149(2 Suppl):S1705. doi: 10.1016/j.jtcvs.2014.08.003
  39. Gornik HL, Creager MA. Aortitis. Circulation. 2008 Jun 10;117(23):303951. doi: 10.1161/CIRCULATIONAHA.107.760686
  40. Leone O, Corsini A, Pacini D, et al. The complex interplay among atherosclerosis, inflammation, and degeneration in ascending thoracic aortic aneurysms. J Thorac Cardiovasc Surg. 2020 Dec;160(6):14341443.e6. doi: 10.1016/j.jtcvs.2019.08.108
  41. Pacini D, Leone O, Turci S, et al. Incidence, etiology, histologic findings, and course of thoracic inflammatory aortopathies. Ann Thorac Surg. 2008 Nov;86(5):151823. doi: 10.1016/j.athoracsur.2008.07.039
  42. Evans JM, O’Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med. 1995 Apr 1;122(7):5027. doi: 10.7326/0003-4819-122-7-199504010-00004
  43. Stone JH, Khosroshahi A, Deshpande V, Stone JR. IgG4-related systemic disease accounts for a significant proportion of thoracic lymphoplasmacytic aortitis cases. Arthritis Care Res (Hoboken). 2010 Mar;62(3):31622. doi: 10.1002/acr.20095
  44. Hellmich B, Agueda A, Monti S, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020 Jan;79(1):1930. doi: 10.1136/annrheumdis-2019-215672
  45. Buttgereit F, Dejaco C, Matteson EL, Dasgupta B. Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review. JAMA. 2016 Jun 14;315(22):244258. doi: 10.1001/jama.2016.5444
  46. Hoffman GS, Cid MC, Hellmann DB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 2002 May;46(5):130918. doi: 10.1002/art.10262
  47. Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum. 2007 Mar;56(3):10009. doi: 10.1002/art.22404
  48. Stone JH, Tuckwell K, Dimonaco S, et al. Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med. 2017 Jul 27;377(4):317328. doi: 10.1056/NEJMoa1613849
  49. Jover JA, Hernández-García C, Morado IC, Vargas E, Bañares A, Fernàndez-Gutiérrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001 Jan 16;134(2):10614. doi: 10.7326/0003-4819-134-2-200101160-00010
  50. ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c2023. Effect of Preoperative Exercise on Postoperative Outcome in AAA Patients: Pilot Study; 2016 Jul 27 [cited 2023 Jan 26]. Available from: https://clinicaltrials.gov/show/NCT02845167
  51. Fuglsang S, Heiberg J, Hjortdal VE, Laustsen S. Exercise-based cardiac rehabilitation in surgically treated type-A aortic dissection patients. Scand Cardiovasc J. 2017 Apr;51(2):99105. doi: 10.1080/14017431.2016.1257149
  52. Evangelista A, Pineda V, Guala A, et al. False Lumen Flow Assessment by Magnetic Resonance Imaging and Long-Term Outcomes in Uncomplicated Aortic Dissection. J Am Coll Cardiol. 2022;79(24):24152427. doi: 10.1016/j.jacc.2022.04.017
DOI: https://doi.org/10.14797/mdcvj.1192 | Journal eISSN: 1947-6108
Language: English
Page range: 70 - 77
Submitted on: Nov 24, 2022
Accepted on: Jan 13, 2023
Published on: Mar 7, 2023
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services

© 2023 Mujtaba Saeed, Maan Malahfji, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.